Salamanca

• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02) Ended
  2024-513993-23-00 9 2022-09-21 Patients with higher risk myelodysplastic syndrome (MDS) who have not
• Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advance … Ended
  2024-514293-46-00 4 2022-07-07 Unresectable locally advanced or metastatic urothelial cancer
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and … Ended
  2023-508734-34-00 10 2022-06-30 Pulmonary Arterial Hypertension (PAH)
• A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Admi … Ended
  2023-506380-33-00 5 2022-06-28 Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer
• A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and re … Ended
  2023-507140-37-00 4 2022-06-22 Adult patients with relapsed and refractory multiple myeloma
• Study to evaluate the efficacy and safety of switching to insulin glargine 300 U/ml from insulin glargine 100 U/ml in patients with type 2 d … Ended
  2024-518403-22-00 6 2022-06-20 Diabetes mellitus II
• To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myelo … Ended
  2024-510644-31-00 3 2022-06-10 Relapsed/Refractory Multiple Myeloma
• Clinical trial developed at various hospitals where each patient randomly receive in parallel groups either placebo or treatment. Nor patien … Ended
  2024-519527-14-00 5 2022-06-09 Allergic rhinoconjunctivitis
• A Phase 1, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma. Ended
  2023-505079-65-00 1 2022-04-01 Multiple myeloma
• A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended
  2024-511560-93-00 5 2022-03-29 Schizophrenia
• Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer Ended
  2023-508828-35-01 5 2022-03-28 Patients with advanced hormone receptor-positive/HER2- negative/HER2-E
• Long-term Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder Ended
  2024-512108-20-00 5 2022-03-16 Obsessive Compulsive Disorder
• A study testing increasing amounts (doses) of CC-91633 to find out what dose can be tolerated without serious side effects in patients with … Ended
  2023-503869-34-00 1 2022-03-15 Acute myeloid leukemia or myelodysplastic syndrome of high risk group,
• A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectivenes … Ended
  2022-501243-33-00 4 2022-02-03 Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s lymphoma, in pa
• EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib … Ended
  2024-513023-17-00 5 2022-01-12 Treatment of acute graft-versus host disease (aGvHD) to the gastrointe
• A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelody … Ended
  2023-506117-22-00 3 2022-01-05 Acute Myeloid Leukemia and Myelodysplastic Syndromes
• A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Plac … Ended
  2024-511066-36-00 5 2021-10-13 Light Chain (AL) Amyloidosis
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Ended
  2023-503387-16-00 4 2021-07-13 Classical Hodgkin Lymphoma
• A research study investigating troriluzole as a possible treatment for Obsessive Compulsive Disorder Ended
  2024-514585-39-00 5 2021-07-12 Obsessive Compulsive Disorder
• HOPE study Ended
  2024-516642-19-01 6 2021-06-16 Acute Ischemic Stroke
• A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cel … Ended
  2023-509155-14-00 4 2021-06-10 Peripheral T-cell Lymphoma
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin … Ended
  2023-510230-84-00 5 2021-05-28 Severe asthma with an eosinophilic phenotype
• Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffus … Ended
  2023-508259-38-00 5 2021-04-29 Adult patients with relapsed or primary refractory DLBCL

Showing 409–432 of 470 trials